Zoledronic acid (ZA) prevents aromatase inhibitor (Al)-associated bone loss in postmenopausal women with early breast cancer -36-month follow-up of the Z-FAST study

2008 ◽  
Vol 6 (7) ◽  
pp. 197 ◽  
Author(s):  
A. Brufskv ◽  
L. Bosserman ◽  
R. Caradonna ◽  
B. Haley ◽  
M. Jones ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Zoledronic Acid ◽  
Bone Loss ◽  
Aromatase Inhibitor ◽  
Postmenopausal Women ◽  
Early Breast Cancer

The protective effect of zoledronic acid on bone loss in postmenopausal women with early breast cancer treated with sequential tamoxifen and letrozole: 36-month follow-up.

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. e11111-e11111 ◽  
Author(s):  
J. Greenberg ◽  
S. M. Stemmer ◽  
R. Bernstein-Molho ◽  
S. Pelles-Avraham ◽  
I. Stephansky ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Zoledronic Acid ◽  
Bone Loss ◽  
Protective Effect ◽  
Postmenopausal Women ◽  
Early Breast Cancer

Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole

Cancer ◽  
2008 ◽  
Vol 112 (5) ◽  
pp. 1001-1010 ◽  
Author(s):  
Nigel J. Bundred ◽  
Ian D. Campbell ◽  
Neville Davidson ◽  
Richard H. DeBoer ◽  
Holger Eidtmann ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Zoledronic Acid ◽  
Bone Loss ◽  
Aromatase Inhibitor ◽  
Postmenopausal Women ◽  
Early Breast Cancer ◽  
Effective Inhibition
Sign in / Sign up

Export Citation Format

Share Document